In the present study, the rates of ALDH1 positivity at a 1 % cutoff value were 18.4 %, 13.4 %, and 8.4 % in patients with early, late, and no recurrence, respectively, among those with ER-positive/HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.